This webinar was funded by Viatris.
Disclaimer: The views and opinions expressed in this webinar are those of the individual speakers and do not necessarily reflect those of Viatris or EMJ. The speaker received honoraria for participating in this webinar. UK Prescribing Information for pimecrolimus can be found here. Adverse Event Reporting can be found at the end of this landing page. For those outside of the UK, please refer to your local guidance as prescribing conditions may vary. All opinions and statements contained in this material and/or made by the speaker are opinions and statements of the speaker resulting from his/her knowledge, research, clinical and professional experience, and the speaker bears full responsibility for them.
In this EMJ webinar, expert dermatologist Beatrix Volc-Platzer joins moderator Sue Saville in exploration of the role of skin barrier dysfunction in the development of atopic dermatitis (AD) and progression along the atopic march.
The discussion highlights the importance of early barrier-focused treatment and its potential to influence disease trajectory.
Topics include:
- Understanding skin barrier dysfunction in atopic dermatitis
- The link between atopic dermatitis and the atopic march
- The role of early barrier-focused treatment in modifying disease trajectory
Timestamps:
00:00–01:56 – Introduction
01:57–04:52 – Overview of the Skin Barrier and Its Importance
04:53–10:09 – Role of Transepidermal Water Loss and Filaggrin
10:10–14:37 – Role of the Skin Barrier in AD and the Atopic March
14:38–17:05 – Risk Factors for AD Progression and Importance of Early Treatment
17:06–19:34 – Treatment Options for Children with AD
19:35–24:25 – Role of Emollients
24:26–32:27 – Role of Topical Anti-inflammatory Treatment
32:28–34:44 – Role of Systemic Treatments
34:45-37:45 – Conclusions
Speaker:
Beatrix Volc-Platzer1
1. Former Chair, Department of Dermatology, SMZ Ost, Vienna, Austria; Board of Directors (until 2023), European Society for Pediatric Dermatology (ESPD)
Disclosures:
Volc-Platzer has received consulting fees, honoraria, and research funding from La Roche Posay, Sanofi, Almirall, and Viatris.
Please continue to report suspected adverse drug reactions and device failures with any medicine or vaccine to the MHRA through the Yellow Card Scheme. It is easiest and quickest to report adverse drug reactions and device failures online via the Yellow Card website: https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.Please report adverse drug reactions to Viatris at 0044 1707 853000 (select Option 5), or email: [email protected]/.
